다약제내성 균주 감염에 대한 Tigecycline의 치료
Tigecycline Treatment for Infections Caused by Multidrug-Resistant Pathogens
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background Tigecycline (TIG), a new broad-spectrum glycylcycline with anti-multidrug-resistant-(MDR)-pathogen activity, was launched in March 2009 in South Korea, but there are insufficient clinical studies on its use in the country. As such, this study was performed to analyze cases of severe MDR-pathogen-caused infections treated with TIG. Methods Patients treated with TIG within the period from May 2009 to June 2010 were enrolled in this study. Their clinical and microbiologic data were reviewed retrospectively. Results Twenty-one patients were treated with TIG for complicated skin and soft-tissue infections (cSSTIs) (42.9%), complicated intra-abdominal infections (cIAIs) (38.1%), or pneumonia (19.1%) caused by MDR pathogens like carbapenem-resistant Acinetobacter baumannii (76.2%), methicillin-resistant Staphylococcus aureus (61.9%), extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae (38.1%), and penicillin-resistant Enterococcus species (33.3%). Thirteen patients (61.9%) had successful clinical outcomes while five (23.8%) died within 30 days. The rate of clinical success was highest in cSSTI (77.8%), followed by cIAI (50%) and pneumonia (50%), and the mortality rate was highest in pneumonia (50%), followed by cIAI (25%) and cSSTI (11.1%). Conclusion Tigecycline therapy can be an option for the treatment of severe MDR-pathogen-caused infections in South Korea. Due to its high risk of failure and mortality, however, prudence is required in its clinical use for the treatment of severe infections like nosocomial pneumonia.
Abstract
Background Tigecycline (TIG), a new broad-spectrum glycylcycline with anti-multidrug-resistant-(MDR)-pathogen activity, was launched in March 2009 in South Korea, but there are insufficient clinical studies on its use in the country. As such, this study was performed to analyze cases of severe MDR-pathogen-caused infections treated with TIG. Methods Patients treated with TIG within the period from May 2009 to June 2010 were enrolled in this study. Their clinical and microbiologic data were reviewed retrospectively. Results Twenty-one patients were treated with TIG for complicated skin and soft-tissue infections (cSSTIs) (42.9%), complicated intra-abdominal infections (cIAIs) (38.1%), or pneumonia (19.1%) caused by MDR pathogens like carbapenem-resistant Acinetobacter baumannii (76.2%), methicillin-resistant Staphylococcus aureus (61.9%), extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae (38.1%), and penicillin-resistant Enterococcus species (33.3%). Thirteen patients (61.9%) had successful clinical outcomes while five (23.8%) died within 30 days. The rate of clinical success was highest in cSSTI (77.8%), followed by cIAI (50%) and pneumonia (50%), and the mortality rate was highest in pneumonia (50%), followed by cIAI (25%) and cSSTI (11.1%). Conclusion Tigecycline therapy can be an option for the treatment of severe MDR-pathogen-caused infections in South Korea. Due to its high risk of failure and mortality, however, prudence is required in its clinical use for the treatment of severe infections like nosocomial pneumonia.
참고문헌 (21)
- Mullangi PK, "Tigecycline in critical care", Crit Care Clin, 24, pp.365~375 (2008)
- Wang YF, "In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008", Diagn Microbiol Infect Dis, 68, pp.73~79 (2010)
- 이미숙, "새로운 항생제의 개발", 대한내과학회지, 77(1), pp.35~51 (2009), 대한내과학회
- Bhattacharya M, "Tigecycline", J Postgrad Med, 55, pp.65~68 (2009)
- Noskin GA, "Tigecycline: a new glycylcycline for treatment of serious infections", Clin Infect Dis, 41(Suppl 5), pp.S303~S314 (2005)
- "Tigecyclien Injection. Bulletin 2009- 257 2010"[URL]
- Ko KS, "Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries", Diagn Microbiol Infect Dis, 55, pp.337~341 (2006)
- Park YK, "In vitro activity of tigecycline against colistin-resistant Acinetobacter spp. isolates from Korea", Int J Antimicrob Agents, 33, pp.289~290 (2009)
- Yahav D, "Efficacy and safety of tigecycline: a systematic review and meta-analysis", J Antimicrob Chemother, 66, pp.1963~1971 (2011)
- Clinical and Laboratory Standards Institute., "Performance standards for antimicrobial susce- ptibility testing; 17th informational supplement", CLSI document M100-S17, ~ (2007)
- Horan TC GR, "Hospital epidemiology and infection control", pp.1659~1702 (2004), Lippincott Williams & Wilkins
- Sader HS, "Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009)", Diagn Microbiol Infect Dis, 69, pp.223~227 (2011)
- Eckmann C, "Prospective, non- interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice", Chemotherapy, 57, pp.275~284 (2011)
- Entenza JM, "Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies", Int J Antimicrob Agents, 34, pp.8~ (2009)
- Rodvold KA, "Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose", J Antimicrob Chemother, 58, pp.1221~1229 (2006)
- Peleg AY, "Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report", J Antimicrob Chemother, 59, pp.128~131 (2007)
- Metan G, "Clinical experience with tigecycline in the treatment of carbapenem- resistant Acinetobacter infections", J Chemother, 22, pp.110~114 (2010)
- Karageorgopoulos DE, "Tigecycline for the treatment of multidrug-resistant (including carbapenem- resistant) Acinetobacter infections: a review of the scientific evidence", J Antimicrob Chemother, 62, pp.45~55 (2008)
- Gordon NC, "A review of clinical and microbiological outcomes following treatment of infections involving multidru", g-resistant Acinetobacter baumannii with tigecycline, 2009, pp.63, 775~780
- Freire AT, "Comparison of tigecycline with imipenem", cilastatin for the treatment of hospital-acquired pneumonia, 2010, pp.68, 140~151
- Burkhardt O, "Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint", Int J Antimicrob Agents, 34, pp.101~102 (2009)